Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

This publication has 25 references indexed in Scilit:

• Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2006
• Disrupting tumour blood vessels
  Nature Reviews Cancer, 2005
• Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
  British Journal of Cancer, 2004
• Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
  Journal of Clinical Oncology, 2003
• Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
  Journal of Clinical Oncology, 2003
• Antivascular therapy of cancer: DMXAA
  The Lancet Oncology, 2003
• Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2002
• Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
  British Journal of Cancer, 2002
• Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid
  British Journal of Cancer, 1995